Nottingham Advisors Inc. Has $835,000 Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Nottingham Advisors Inc. lowered its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 47.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,828 shares of the biopharmaceutical company’s stock after selling 87,938 shares during the period. Nottingham Advisors Inc. owned approximately 0.06% of Ocular Therapeutix worth $835,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. AlphaQuest LLC acquired a new position in Ocular Therapeutix during the fourth quarter valued at $53,000. Palumbo Wealth Management LLC acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at about $100,000. Cibc World Markets Corp acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at about $124,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Ocular Therapeutix in the fourth quarter worth approximately $149,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Ocular Therapeutix during the fourth quarter worth approximately $159,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on OCUL. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price objective on the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC assumed coverage on Ocular Therapeutix in a research report on Tuesday, March 11th. They set a “buy” rating and a $15.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.38.

Ocular Therapeutix Price Performance

NASDAQ OCUL opened at $7.34 on Thursday. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.78. The stock’s 50-day moving average is $7.47 and its two-hundred day moving average is $8.72. The firm has a market cap of $1.17 billion, a P/E ratio of -5.56 and a beta of 1.49. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Insider Transactions at Ocular Therapeutix

In related news, insider Donald Notman sold 6,301 shares of Ocular Therapeutix stock in a transaction on Friday, January 31st. The shares were sold at an average price of $7.84, for a total value of $49,399.84. Following the transaction, the insider now owns 204,563 shares in the company, valued at $1,603,773.92. This trade represents a 2.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. This represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,895 shares of company stock worth $283,772. 3.50% of the stock is owned by insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.